Risk of Ischemic Stroke Associated With Calcium Supplements With or Without Vitamin D: A Nested Case-Control Study.
Study Goal
The researchers aimed to determine whether calcium supplements, either alone or combined with vitamin D, increase the risk of ischemic stroke.
Results Summary
Calcium monotherapy at high doses (≥1000 mg/day) was associated with an increased risk of ischemic stroke, while calcium combined with vitamin D showed no increased risk. The findings were consistent across different conditions and among new users.
Population
Patients aged 40 to 89 years, including 2,690 cases of first nonfatal ischemic stroke and 19,538 controls.
Effective Dosage
High dose: ≥1000 mg/day; lower dose: <1000 mg/day.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Calcium supplementation with vitamin D | no change | ischemic stroke | patients aged 40 to 89 years old | odds ratio 0.85; 95% confidence interval, 0.67-1.08 | was not associated with an increased risk | #1 |
Calcium supplement monotherapy | no change | ischemic stroke | patients aged 40 to 89 years old | odds ratio 1.18; 95% confidence interval, 0.86-1.61 | was not associated with an increased risk | #2 |
Calcium supplement monotherapy at high doses (≥1000 mg/day) | increase | ischemic stroke | patients aged 40 to 89 years old | odds ratio 2.09; 95% confidence interval, 1.25-3.49 | a significant increased risk | #3 |
Calcium supplement monotherapy at doses <1000 mg/day | no change | ischemic stroke | patients aged 40 to 89 years old | odds ratio 0.76; 95% confidence interval, 0.45-1.26 | was not associated with an increased risk | #4 |
BACKGROUND: There is controversy surrounding the risk of ischemic stroke associated with the use of calcium supplements either in monotherapy or in combination with vitamin D. METHODS AND RESULTS: A nested case-control study was performed with patients aged 40 to 89 years old, among whom a total of 2690 patients had a first episode of nonfatal ischemic stroke and for which 19 538 controls were randomly selected from the source population and frequency-matched with cases for age, sex, and calendar year. Logistic regression provided the odds ratios while adjusting for confounding factors. A sensitivity analysis was performed by restricting to patients who were new users of calcium supplements as either monotherapy or with vitamin D. Calcium supplementation with vitamin D was not associated with an increased risk of ischemic stroke (odds ratio 0.85; 95% confidence interval, 0.67-1.08) in the population as a whole or under any of the conditions examined (dose, duration, background cardiovascular risk, sex, or age). Calcium supplement monotherapy was not associated with an increased risk in the population as a whole (odds ratio 1.18; 95% confidence interval, 0.86-1.61), although a significant increased risk at high doses (≥1000 mg/day: odds ratio 2.09; 95% confidence interval, 1.25-3.49; <1000 mg: odds ratio 0.76; 95% confidence interval, 0.45-1.26) compared with nonuse was observed. The sensitivity analysis did not affect the inferences, with similar results observed among new users as to the overall study population. CONCLUSIONS: This study suggests that calcium supplements given as monotherapy at high doses may increase the risk of ischemic stroke, whereas their combination with vitamin D seems to offset this hazard.